Search Results - Barbara Ink

  • Showing 1 - 10 results of 10
Refine Results
  1. 1

    Comment on: Comparative short-term risks of infection and serious infection in patients receiving biologic and small-molecule therapies for psoriasis and psoriatic arthritis: a sys... by Barbara Ink, Rajan Bajracharya, Vishvesh Shende

    Published in Therapeutic Advances in Chronic Disease (2024-11-01)
    Get full text
    Article


  2. 2

    Bimekizumab provided rapid improvements in patient-reported symptoms and health-related quality of life in patients with active psoriatic arthritis: pooled 16-week results from two... by Joseph F Merola, Philip J Mease, Dafna D Gladman, M Elaine Husni, Nadine Goldammer, Jason Coarse, William Tillett, Vanessa Taieb, Jeremy Lambert, Barbara Ink

    Published in RMD Open (2024-09-01)
    Get full text
    Article


  3. 3

    Validity and score interpretation of the 12-item Psoriatic Arthritis Impact of Disease: an analysis of pooled data from two phase 3 trials of bimekizumab in patients with psoriatic... by Laure Gossec, Ana-Maria Orbai, Maarten de Wit, Dafna D Gladman, Laura C Coates, Alexis Ogdie, Vanessa Taieb, Jeremy Lambert, Barbara Ink, Christopher G Pelligra, Valérie Ciaravino

    Published in RMD Open (2024-01-01)
    Get full text
    Article


  4. 4

    Efficacy and Safety of Bimekizumab in Patients With Psoriatic Arthritis With or Without Methotrexate: 52‐Week Results From Two Phase 3 Studies by Iain B. McInnes, Philip J. Mease, Yoshiya Tanaka, Laure Gossec, M. Elaine Husni, Lars Erik Kristensen, Richard B. Warren, Barbara Ink, Rajan Bajracharya, Jason Coarse, Alice B. Gottlieb

    Published in ACR Open Rheumatology (2024-11-01)
    Get full text
    Article


  5. 5

    Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies by Robert Landewé, Ana-Maria Orbai, Philip J Mease, Denis Poddubnyy, Lianne S Gensler, Vishvesh Shende, Richard B Warren, Luke Peterson, Alexander Marten, Ute Massow, Katy White, Barbara Ink, Rajan Bajracharya, Myriam Manente

    Published in RMD Open (2025-04-01)
    Get full text
    Article


  6. 6

    Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III... by Lars Erik Kristensen, William Tillett, Peter Nash, Laura C. Coates, Philip J. Mease, Alexis Ogdie, Paolo Gisondi, Barbara Ink, Adam R. Prickett, Rajan Bajracharya, Vanessa Taieb, Nikos Lyris, Jérémy Lambert, Jessica A. Walsh

    Get full text
    Article


  7. 7

    Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies by Philip J. Mease, Joseph F. Merola, Yoshiya Tanaka, Laure Gossec, Iain B. McInnes, Christopher T. Ritchlin, Robert B. M. Landewé, Akihiko Asahina, Barbara Ink, Andrea Heinrichs, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Laura C. Coates

    Published in Rheumatology and Therapy (2024-08-01)
    Get full text
    Article


  8. 8

    Correction: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies by Philip J. Mease, Joseph F. Merola, Yoshiya Tanaka, Laure Gossec, Iain B. McInnes, Christopher T. Ritchlin, Robert B. M. Landewé, Akihiko Asahina, Barbara Ink, Andrea Heinrichs, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Laura C. Coates

    Published in Rheumatology and Therapy (2025-05-01)
    Get full text
    Article


  9. 9

    Summary of Research: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies by Philip J. Mease, Joseph F. Merola, Yoshiya Tanaka, Laure Gossec, Iain B. McInnes, Christopher T. Ritchlin, Robert B. M. Landewé, Akihiko Asahina, Barbara Ink, Andrea Heinrichs, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Laura C. Coates

    Published in Rheumatology and Therapy (2025-05-01)
    Get full text
    Article


  10. 10

    Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III... by Robert Landewé, Joseph F Merola, Laure Gossec, Frank Behrens, Ana-Maria Orbai, Philip J Mease, Iain B McInnes, Yoshiya Tanaka, Dafna D Gladman, Laura C Coates, Alice B Gottlieb, Vishvesh Shende, Jason Coarse, Christopher T Ritchlin, Richard B Warren, Akihiko Asahina, Barbara Ink, Rajan Bajracharya

    Published in RMD Open (2024-02-01)
    Get full text
    Article


Search Tools: